SCHEMBL1340889

SCHEMBL1340889

O=C(Nc1nc(CSc2ccccc2)c(Cl)s1)Nc1ccc(C(F)(F)F)cc1C(=O)C1CCCC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 3/20 0.37
MAPT P10636 3/20 0.36
TP53 P04637 1/20 0.36
LMNA P02545 2/20 0.36
MEN1 O00255 1/20 0.36
HTT P42858 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
RXFP1 Q9HBX9 4/20 0.35
NTRK1 P04629 2/20 0.35
IDH2 P48735 1/20 0.35
CCNC P24863 1/20 0.35
CDK8 P49336 1/20 0.35
NTRK2 Q16620 1/20 0.35
ADRB2 P07550 1/20 0.34
HRH1 P35367 1/20 0.34
DRD3 P35462 1/20 0.34
CCR2 P41597 1/20 0.34
GLP1R P43220 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1343651 0.91 CSNK1D (0.37) CSNK1DMAPTTP53LMNAMEN1
SCHEMBL1341439 0.90 RAB9A (0.39) MAPTTP53LMNAMEN1HTT
SCHEMBL1341158 0.89 MAPT (0.39) MAPTTP53LMNAMEN1HTT
SCHEMBL1341266 0.89 CCR2 (0.38) CSNK1DMAPTTP53RXFP1NTRK1
SCHEMBL1341534 0.88 TP53 (0.37) CSNK1DMAPTTP53LMNAMEN1
SCHEMBL1340598 0.88 KMT2A (0.39) MAPTLMNAMEN1HTTRAB9A
SCHEMBL2650087 0.88 MAPT (0.38) MAPTTP53LMNAMEN1HTT
SCHEMBL1342721 0.88 MAPT (0.38) MAPTTP53LMNAMEN1HTT
SCHEMBL1342523 0.87 GCK (0.40) CSNK1DMAPTLMNAMEN1KMT2A
SCHEMBL1343364 0.86 MAPT (0.42) MAPTTP53LMNAMEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063081-B2 N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-11-22 US disclosed
US-7897628-B2 {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-03-01 US disclosed
EP-1531815-A1 GLUCOKINASE ACTIVATORS NOVO NORDISK A/S (DK) 2005-05-25 EP disclosed
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents VTV THERAPEUTICS LLC 2004-06-24 US disclosed
WO-2004002481-A1 ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS NOVO NORDISK A/S (DK) 2004-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents GCK, GCKR, PDK2 CSNK1D 1591/4885MAPT 2678/4885TP53 2961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.